Ipamorelin: What It Is and Its U.S. Regulatory Status

What is ipamorelin?

Ipamorelin is a synthetic peptide made of five amino acids that acts on the ghrelin receptor to trigger the release of growth hormone. It is not FDA-approved for any use, and no approved medicine in the United States contains it.

It belongs to a group called growth hormone secretagogues. Ipamorelin was developed at Novo Nordisk in the 1990s. A 1998 study in pigs described it as the first selective compound of this kind, because in that study it released growth hormone without the rises in stress hormones such as cortisol seen with earlier compounds.

How it works

Ghrelin is a hormone made mainly in the stomach. Its receptor on the pituitary gland, called the growth hormone secretagogue receptor, signals the release of growth hormone. Ipamorelin mimics ghrelin at this receptor. Because ghrelin also affects how the gut moves, ipamorelin was tested as a possible way to speed bowel recovery after surgery.

Clinical trials

The main human research tested ipamorelin for postoperative ileus, a temporary slowdown of the bowel after abdominal surgery. In a multicenter phase 2 trial published in 2014, 117 adults having bowel resection were randomly assigned to ipamorelin or placebo, given intravenously. The median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference that was not statistically significant.

Ipamorelin did not advance to approval for that or any other use. There are no large trials of it in healthy adults or for age-related changes in growth hormone.

U.S. regulatory status

Current status: Not FDA-approved.

Ipamorelin's compounding history:

  • September 2023: the FDA placed ipamorelin acetate in Category 2 of its interim compounding lists, the group of bulk substances that raise significant safety risks.
  • 2024: it was removed from the 503A Category 2 list after the nominations were withdrawn.
  • October 29, 2024: the FDA's Pharmacy Compounding Advisory Committee reviewed ipamorelin for growth hormone deficiency and postoperative ileus. It voted 12 to 0, with 1 abstention, against adding ipamorelin acetate or ipamorelin free base to the 503A bulks list, citing a lack of information supporting safety and effectiveness.

As of the FDA's May 14, 2026 list, ipamorelin is not on the 503A bulks list and is not in Category 1. The FDA's safety page still lists ipamorelin acetate in Category 2 under the separate interim policy for 503B outsourcing facilities. Products labeled "for research purposes only" or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents, purity or quality.

Documented safety information

The FDA's safety summary says compounded ipamorelin acetate may pose a risk of immunogenicity (an unwanted immune response) for certain routes of administration because of possible aggregation or peptide-related impurities. It notes that ipamorelin contains unnatural amino acids, which make it harder to characterize. The FDA also cites a published study that identified serious adverse events, including death, when ipamorelin was given intravenously to improve gastric motility.

Sport

The World Anti-Doping Agency (WADA) 2026 Prohibited List names ipamorelin as a growth hormone secretagogue under class S2. It is prohibited at all times, in and out of competition.

Why Peptide Labs does not sell ipamorelin

Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply, prepare or distribute ipamorelin in any form, and nothing on this page should be read as an offer.

For personal medical questions, including questions about growth hormone, the right person to ask is a licensed healthcare provider.

Related reading

See the full list of compound profiles in the Peptide Guide. Related profiles: CJC-1295, the CJC-1295 and ipamorelin blend, GHRP-2 and the FDA-approved tesamorelin. We compare it with sermorelin and tesamorelin in tesamorelin vs sermorelin vs ipamorelin.